home / stock / pirs / pirs news

PIRS News and Press, Pieris Pharmaceuticals Inc. From 11/01/22

Stock Information
Company Name: Pieris Pharmaceuticals Inc.
Stock Symbol: PIRS
Market: NASDAQ
Website: pieris.com
Menu
PIRS PIRS Quote PIRS Short PIRS News PIRS Articles PIRS Message Board
Get PIRS Alerts

News, Short Squeeze, Breakout and More Instantly...
PIRS - Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

BOSTON, MA / ACCESSWIRE / November 1, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, tod...
PIRS - Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022

BOSTON, MA / ACCESSWIRE / October 26, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today ...

PIRS - Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, tod...

PIRS - Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS

BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, toda...
PIRS - Pieris Pharma stock falls ~7% on Q2 earnings miss, discontinuation of a phase 2 study

Shares of micro-cap clinical-stage biotech Pieris Pharmaceuticals ( NASDAQ: PIRS ) have lost 7.4% to $1.69 in Thursday mid-day trading, after the company reported Q2 results that missed estimates and said it would discontinue a phase 2 trial. PIRS posted Q2 GAAP EP...

PIRS - Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M

Pieris Pharmaceuticals press release ( NASDAQ: PIRS ): Q2 GAAP EPS of -$0.14 misses by $0.03 . Revenue of $3.7M (+12.5% Y/Y) misses by $6.77M . Cash, equivalents, and investments totaled $80.9 million for the quarter ended June 30, 2022, compared to a cash and ...

PIRS - Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDT Adjustments to PRS-060/AZD1402 phase 2 study design boost enrollment rate and facilitate a topline readout by 3Q23 Cinrebafusp alfa (PRS-343) demonstrating clinical benefit in HER2-expressing ga...
PIRS - Pieris Pharmaceuticals Q2 2022 Earnings Preview

Pieris Pharmaceuticals ( NASDAQ: PIRS ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.20 (+20.0% Y/Y) and the consensus Revenue Estimate is $10.47M (+218.2% Y/Y). Over the last 3 months, EPS ...

PIRS - Notable earnings before Thursday's open

ABMD , ABUS , ACIW , ADAP , OTCQX:ADDYY , ADT , AG , AGIO , AHH , APD , APO , APTV , ARW , ATI , AUPH , AUTL , AZEK , BABA , BALL , BALY , OTCPK:BAYZF , BCE , BCRX , BDX , BKI , CBRE , ...

PIRS - Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022

BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today ann...
Previous 10 Next 10